Name
BioMarin Pharmaceuticals
Description
In 2018, BioMarin continued to pursue bold science and to work toward changing the practice of medicine in rare genetic diseases. We drove our business forward as we accomplished one product approval in the U.S. and reached several key milestones for two product candidates in Phase 3 of development. Scientifically, we seek to correct serious genetic diseases either by replacing what is missing or prompting the body itself to start providing what it needs. Our goal is to help the communities of people with rare diseases perform biologically the same as or similarly to people without disease.
Website